In-vitro response of platelet aggregation induced by agonists in chronic smoking coronary artery patients

WOS: 00017098830276

The effect of type II diabetes mellitus on platelet aggregation in patients who underwent percutaneous transluminal coronary angioplasty

WOS: 000174768500006PubMed ID: 11917198Background In noninsulin-dependent type II diabetic (tIIDM) patients it was reported that ADP-induced platelet aggregation response was increased with decreased level of platelet guanylate cyclase, This study was therefore designed to examine the effects of tIIDM on collagen-induced, in-vitro platelet aggregation in percutaneous transluminal coronary angioplasty (PTCA) patients, Methods Twenty patients with tIIDM and 30 nondiabetic patients who had successful PTCA were included in the study. Platelet-rich plasma samples from the patients before and after PTCA were treated with in-vitro Collagen and platelet aggregation waves were calculated via the turbidometric method of Born. The maximum amplitude (%) and the ratio of changes after PTCA in the study participants were measured by these waves and data were compared by student's t tests and nonparametric methods. The maximum amplitude of collagen-induced platelet aggregation before and after the procedure was also compared using variant analysis. Results The change in collagen-induced maximum amplitude of platelet aggregation in both wave I and wave 2 was significantly more (P < 0.001- P < 0.001) in the tIIDM group. The ratio of restenosis seen in the control coronary angiography made 6 months after intervention was found to be significantly more in the tIIDM group (P < 0.05). Conclusions Collagen-induced platelet aggregation response was greater in patients with tIIDM than in nondiabetic patients. This makes us think that tIIDM patients could need more potent antiplatelet therapy before PTCA after the blood glucose levels have been regulated, Coron Artery Dis 13:45-48 (C) 2002 Lippincott Williams & Wilkins

Vena cava superior syndrome due to sternal plasmacytoma in the course of systemic myeloma

WOS: 000183326800025PubMed ID: 12803129Here we present a patient with multiple myeloma course. The first clinical manifestation was superior vena cava syndrome due to a huge sternal plasmocytoma. The patient was treated with a combination of high dose radiotherapy and autologous peripheral blood stem cell transplantation. We suggest careful evaluation of these patients with respect to aggressive therapy

Role of protein phosphatases inhibitors in selenium-induced apoptosis in human hepatoma HepG2 cells

38th Annual Meeting of the European-Association-for-the-Study-of-the-Liver -- MAR 29-APR 01, 2003 -- ISTANBUL, TURKEYWOS: 000182174500291European Assoc Study Live

Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease.

45th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2003 -- SAN DIEGO, CALIFORNIAWOS: 000186537100603Amer Soc Hemato